BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 24993731)

  • 21. Dynamics of hepatitis B virus resistance substitutions correlates with virological response in lamivudine-refractory patients with entecavir rescue monotherapy.
    Zhang Y; He S; Li QL; Guo JJ
    Virus Res; 2013 Nov; 177(2):156-62. PubMed ID: 23968804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
    Cai S; Yu T; Jiang Y; Zhang Y; Lv F; Peng J
    Clin Exp Med; 2016 Aug; 16(3):429-36. PubMed ID: 26164128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance.
    Cho SW; Koh KH; Cheong JY; Lee MH; Hong SP; Yoo WD; Kim SO
    J Viral Hepat; 2010 Mar; 17(3):171-7. PubMed ID: 19678894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adefovir-based combination therapy with entecavir or lamivudine for patients with entecavir-refractory chronic hepatitis B.
    Kim SS; Cheong JY; Lee D; Lee MH; Hong SP; Kim SO; Cho SW
    J Med Virol; 2012 Jan; 84(1):18-25. PubMed ID: 22028068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simple scoring system predicting genotypic resistance during rescue therapy for Lamivudine-resistant chronic hepatitis B.
    Lee JH; Yoon JH; Cho EJ; Yang HJ; Jang ES; Kwak MS; Hwang SY; Yu SJ; Lee CH; Kim YJ; Kim CY; Lee HS
    J Clin Gastroenterol; 2012 Mar; 46(3):243-50. PubMed ID: 21716122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clonal evolution of multidrug resistant hepatitis B virus during entecavir rescue therapy.
    Chon YE; Jin B; Ahn SH; Kim S; Kim ND; Park JH; Nam CM; Kim KH; Hong SP; Choi SH; Kim DY; Park JY; Han KH
    Liver Int; 2015 Nov; 35(11):2370-83. PubMed ID: 25872678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficacy and safety of Entecavir monotherapy switched from Lamivudine combined Adefovir Dipivoxil for chronic hepatitis B virus-related compensated liver cirrhosis].
    Lai XJ; Lian JS; Chen JY; Zhang YM; Jia HY; Zheng L; Yang YD
    Zhonghua Gan Zang Bing Za Zhi; 2018 Feb; 26(2):113-118. PubMed ID: 29804377
    [No Abstract]   [Full Text] [Related]  

  • 28. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.
    Yatsuji H; Suzuki F; Sezaki H; Akuta N; Suzuki Y; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Watahiki S; Iwasaki S; Kobayashi M; Kumada H
    J Hepatol; 2008 Jun; 48(6):923-31. PubMed ID: 18433925
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir.
    Ze E; Baek EK; Lee JJ; Chung HW; Ahn DG; Cho HJ; Kwon JC; Kim HJ; Lee H
    Clin Mol Hepatol; 2014 Sep; 20(3):267-73. PubMed ID: 25320730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response.
    Woo HY; Park JY; Bae SH; Kim CW; Jang JY; Tak WY; Kim DJ; Kim IH; Heo J; Ahn SH
    Clin Mol Hepatol; 2020 Jul; 26(3):352-363. PubMed ID: 32460460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B.
    Ryu HJ; Lee JM; Ahn SH; Kim DY; Lee MH; Han KH; Chon CY; Park JY
    J Med Virol; 2010 Nov; 82(11):1835-42. PubMed ID: 20872709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir.
    Lim YS; Lee JY; Lee D; Shim JH; Lee HC; Lee YS; Suh DJ
    Antimicrob Agents Chemother; 2012 Jun; 56(6):2941-7. PubMed ID: 22430972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Entecavir plus adefovir combination therapy versus lamivudine add-on adefovir for lamivudine-resistant chronic hepatitis B: A meta-analysis.
    Zeng T; Xu H; Liu JY; Lei Y; Zhong S; Zhou Z
    J Clin Pharmacol; 2014 Sep; 54(9):959-67. PubMed ID: 24964070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the efficacies of entecavir 0.5 and 1.0 mg combined with adefovir in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analogue treatments.
    Cho Y; Lee JH; Yu SJ; Yoon JH; Lee HS; Kim YJ
    J Med Virol; 2015 Jun; 87(6):999-1007. PubMed ID: 25711201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of entecavir and adefovir combination therapy for patients with lamivudine- and entecavir-resistant chronic hepatitis B.
    Jeon JW; Shin HP; Lee JI; Joo KR; Cha JM; Park JJ; Lim JU; Lim K; Kim S
    Dig Dis Sci; 2012 May; 57(5):1358-65. PubMed ID: 22134785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
    Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term efficacy of entecavir in adefovir-refractory chronic hepatitis B patients with prior lamivudine resistance.
    Park JW; Kim HS; Seo DD; Jang JS; Shin WG; Kim KH; Jang MK; Lee JH; Kim HY; Kim DJ; Lee MS; Park CK
    J Viral Hepat; 2011 Oct; 18(10):e475-81. PubMed ID: 21914066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rescue therapy for lamivudine-resistant chronic hepatitis B: adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy.
    Ha M; Zhang G; Diao S; Lin M; Wu J; Sun L; She H; Shen L; Huang C; Shen W; Huang Z
    Intern Med; 2012; 51(12):1509-15. PubMed ID: 22728482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of 2years of entecavir plus adefovir therapy in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analog treatment.
    Wang X; Zhang C; Zhu Y; Xiong Y; Wang Y
    Antiviral Res; 2014 Mar; 103():71-7. PubMed ID: 24462954
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment.
    Kim HJ; Park SK; Yang HJ; Jung YS; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Choi KY
    Clin Mol Hepatol; 2016 Sep; 22(3):350-358. PubMed ID: 27729626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.